Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567716 | 0.93 | ALDH1A1 (0.43) | PLAUF2EPHX2SMN1; SMN2POLB | |
| SCHEMBL5568169 | 0.91 | ALDH1A1 (0.51) | HPGDF2SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5568637 | 0.91 | MAPT (0.42) | PLAUF2F10EPHX2SMN1; SMN2 | |
| SCHEMBL5567456 | 0.89 | ALDH1A1 (0.52) | F2PRSS1EPHX2SMN1; SMN2ALDH1A1 | |
| SCHEMBL5565590 | 0.88 | ALDH1A1 (0.42) | PLAUGAAHPGDF2F10 | |
| SCHEMBL5563505 | 0.88 | UBE2N (0.45) | F2F10PRSS1SMN1; SMN2POLB | |
| SCHEMBL5563126 | 0.87 | NOTUM (0.48) | GAAHPGDSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL5565420 | 0.85 | KDM4E (0.41) | HPGDF2F10PRSS1EPHX2 | |
| SCHEMBL5563884 | 0.84 | KDM4E (0.40) | HPGDF2F10PRSS1SMN1; SMN2 | |
| SCHEMBL5568085 | 0.83 | NPC1 (0.42) | GAAF2F10SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247654-B2 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-24 | — | — | US | claimed |
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | TFPI, HABP2, TFPI2 | PLAU 57/4885GAA 873/4885HPGD 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.